- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/545 - Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 239/545
Total number of patents in this class: 120
10-year publication summary
|
10
|
9
|
5
|
7
|
10
|
9
|
9
|
10
|
6
|
4
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| MyoKardia, Inc. | 114 |
9 |
| Georgy Viktorovich TETS | 22 |
5 |
| Omeros Corporation | 306 |
5 |
| Viktor Veniaminovich TETS | 23 |
5 |
| Bristol-myers Squibb Company | 4757 |
3 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 877 |
3 |
| The Regents of the University of California | 20902 |
2 |
| Bayer Pharma AG | 1005 |
2 |
| Amgen Inc. | 4467 |
2 |
| Dow AgroSciences LLC | 1179 |
2 |
| ACEA Biosciences, Inc. | 21 |
2 |
| Allergan Sales, LLC | 249 |
2 |
| Assia Chemical Industries Ltd. | 241 |
2 |
| Baylor College of Medicine | 1012 |
2 |
| Gilead Sciences, Inc. | 2247 |
2 |
| Hangzhou Adamerck Pharmlabs Inc. | 16 |
2 |
| Monash University | 733 |
2 |
| Shionogi & Co., Ltd. | 886 |
2 |
| Teva Pharmaceuticals International GmbH | 326 |
2 |
| The University of Melbourne | 572 |
2 |
| Other owners | 62 |